Prerenalism—A Gap That Costs Lives, Hearts, and Kidneys

Figures

• 

  Figure 1.. Heat Maps and Bar Graph Showing Severity and Prevalence of Diagnosed and Undiagnosed CKD at Baseline in the FINEARTS-HF Trial KDIGO risk categories are listed as follows: diagnosed CKD (A), undiagnosed CKD (B), and prevalence of diagnosed and undiagnosed CKD at baseline, overall, and in key subgroups (C). Within the CKD staging components, A refers to the stage and/or severity of albuminuria, and G refers to the stage and/or severity of estimated glomerular filtration rate reduction. CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; FINEARTS-HF, Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure; KDIGO, Kidney Disease: Improving Global Outcomes; LVEF, left ventricular ejection fraction; T2D, type 2 diabetes; UACR, urine albumin to creatinine ratio.

• 

  Figure 2.. Cumulative Incidence Curve and Forest Plots Showing the Clinical Outcomes and Effects of Finerenone in the FINEARTS-HF trial by CKD Status at Baseline Figure shows the cumulative incidence of the primary composite end point of CV death and total HF events according to baseline CKD status (A), the association between CKD and the rate of the primary composite end point (B), and treatment effects of finerenone vs placebo by baseline CKD status (C). Semiparametric proportional hazards models in (B) adjusted for age, sex, geographic region, left ventricular ejection fraction, randomized treatment, smoking status, diabetes status, history of atherosclerotic cardiovascular disease, history of atrial fibrillation, history of chronic obstructive pulmonary disease, New York Heart Association functional class, body mass index, systolic blood pressure, glycated hemoglobin, log-transformed N-terminal prohormone of B-type natriuretic peptide, and baseline sodium-glucose cotransporter 2 inhibitor use. CKD indicates chronic kidney disease; CV, cardiovascular; FINEARTS-HF, Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure; HF, heart failure;…